A Drug & Medical Device Recall And/Or Safety Alert Has Been Issued: Revlimid (lenalidomide): Ongoing Safety Review – Increased Risk of Developing New Malignancies. According to the Food & Drug Administration FDA’s MedWatch:
UPDATED 05/07/2012. Increased risk of developing acute myelogenous leukemia, myelodysplastic syndromes, and Hodgkin lymphoma in patients being treated with Revlimid.
For more information on the drug or medical device recall or safety alert, read the Food & Drug Administration’s FDA’s drug or medical device recall or safety alert: Revlimid (lenalidomide): Ongoing Safety Review – Increased Risk of Developing New Malignancies.
To report an adverse reaction, problem or other issue with a drug or medical device, submit a drug or medical device complaint to the government at fda.gov or MedWatch.
If you have thoughts on the drug or medical device recall or safety alert, share your drug or medical device recall or safety alert comments below.